In the pipeline from Derek Lowe – Page 7
-
OpinionMessy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
OpinionTools of the trade
Derek Lowe wonders what the most life-changing instrument for organic chemists is, and what might be missing from the toolbox
-
OpinionBeelzebub Pharma Ltd
Derek Lowe thinks the Devil’s R&D management schemes might be scarily familiar
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
OpinionNatural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
-
OpinionWhat's the use?
Not every reaction can be run in a bucket, says Derek Lowe, but there are limits to what should be classed as ‘useful’
-
-
OpinionKnowledge lost or time gained?
Derek Lowe wonders whether we should mourn the decline of classic analytical techniques or embrace technological advances
-
OpinionLab’s labourers lost?
How long should scientists stay at the bench, asks Derek Lowe. How long is a piece of string?
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
OpinionBespoke or bodged
A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe
-
Opinion
From lab to leader
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
OpinionName reactions: how does the label stick?
Derek Lowe investigates the long running tradition of naming reactions after their inventors
-
OpinionFear of the unknown
How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe
-
OpinionFull disclosure?
The pharma industry should be more open with its trial data, says Derek Lowe
-
Opinion
High finance meets big pharma?
Derek Lowe examines an alternative funding model for pharmaceutical research